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Hyperfiltration and renal disease in glycogen storage disease, type I. A
prospective study of 14 patients (ages 6 months to 33 years) with
glycogen storage disease, Type I (GSD-1) was carried out in order to
define the character and frequency of renal dysfunction. A marked
increase in the glomerular filtration rate (GFR) was documented in
virtually all subjects, with the mean GFR raised by approximately 50%,
to the range of 170 mI/mm/I .73 m2. While this constituted the only renal
abnormality found in the younger patients, a significant increase in
urinary albumin excretion was seen in three teen-aged individuals; three
patients over 20 years of age exhibited frank proteinuria (2 to 8 g/day).
Renal biopsy on two of the proteinuric subjects revealed focal and
global glomerulosclerosis and interstitial fibrosis. Evaluation of factors
known to cause an increase in GFR did not define the precise etiology
for its elevation in GSD-l. These studies suggest that: (I) glomerular
damage and chronic renal disease are common in older patients with
GSD-1; (2) the renal injury appears to be specifically related to GSD-I
and is not secondary to the treatment of the disease; and (3) the natural
history of the renal lesion in GSD-l may be analogous to that seen in
insulin-dependent diabetes, with a "silent" period where hyperfiltration
is the only demonstrable renal abnormality, followed by evidence of
increasing glomerular damage progressing from microalbuminuria to
frank proteinuria.
Type I glycogen storage disease (GSD-I) is caused by a
congenital in vivo deficiency of glucose-6-phosphatase activity,
normally present in the liver, kidney and intestine. The glucose-
6-phosphatase enzyme is absent in type IA GSD; microsomal
translocase enzymes are absent in types lB and IC [1—3].
Glucose-6-phosphatase normally liberates free glucose from the
glucose-6-phosphate produced via gluconeogenic and glycoge-
nolytic pathways. Prominent clinical features of GSD-I include
hypoglycemia on brief fasting, lactic acidosis, hypertriglyceri-
demia, hyperuricemia, growth failure, hepatomegaly, renal
enlargement, and bleeding diathesis [1]. These abnormalities
are reversed or markedly improved when fasting is avoided [4].
Several patients with GSD-I have been noted to develop renal
dysfunction [5—7]. This problem was initially felt to be a
complication of chronic hyperuricemia since necropsy findings
were interpreted as diagnostic of uric acid nephropathy [5].
However, the use of xanthine oxidase inhibitors, together with
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the improved metabolic control brought about by frequent
feeding plus overnight intragastric glucose infusion and corn-
starch regimens, has resulted in normal to near-normal levels of
serum uric acid [4]. Urate nephropathy as a complication of
GSD-I might then have been expected to be eliminated. In
addition, the entity of chronic uric acid nephropathy as a cause
of renal insufficiency has itself been questioned [8].
The problem of chronic renal disease in GSD-I has received
new interest; a recent report [9] showed that ten of eleven
patients over 20 years of age had evidence of significant renal
damage (proteinuria, hypertension, or decreased creatinine
clearance). Three of the patients had died because of renal
failure. Hyperuricemia had been controlled in recent years, and
urinary tract infections were not unusually common. Renal
biopsies in three patients demonstrated focal segmental glomer-
ulosclerosis and interstitial fibrosis.
In evaluating one of our patients with GSD-I and proteinuria,
an extremely high glomerular filtration rate (GFR) was found.
The renal biopsy of this patient also showed focal glomerulo-
sclerosis and interstitial fibrosis. These pathological findings are
consistent with the renal lesion seen when glomerular hyperfil-
tration is induced in experimental animal models [10]. Prelimi-
nary studies on several other GSD-1 patients revealed elevated
creatinine clearance, reflecting glomerular hyperfiltration. A
prospective study was then initiated, the purpose of which was
to define the character and frequency of renal dysfunction in a
population of GSD-I patients of varying ages, with particular
emphasis on the prevalence of glomerular hyperfiltration in this
population.
Methods
Subjects
Fourteen patients with GSD-I are followed at Children's
Hospital of Philadelphia. They all were contacted and agreed to
participate in this study. The patients ranged in age from 6
months to 33-2/12 years. Two of the patients were related
(brothers). The study protocol was approved by the Committee
for Protection of Human Subjects of The Children's Hospital of
Philadelphia. Informed consent was obtained from all patients
capable of understanding and from all parents.
Experimental protocol
All studies were carried out in the Clinical Research Center of
The Children's Hospital of Philadelphia. The patients were
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Irregular compliance
Table 1. Clinical characteristics of the GSD-l patients
maintained on their home dietary and medication regimen.
From each patient, timed urine collections were obtained for
determination of GFR by creatinine clearance, total protein,
albumin, and urea nitrogen. Values from replicate specimens
were averaged. Four patients had inulin clearance determina-
tions of GFR, and 11 patients had GFR determined by 99mTc..
DTPA clearance [11]. Thirteen of the subjects had GFR deter-
mined by two different methods. Dietary protein intake was
evaluated by recall of the home regimen and by measurement of
a timed urine collection for urea nitrogen [121. The results were
then expressed as percent of RDA recommendations for age
[13]. Thirteen patients had renal ultrasonography [14]. Serum
levels of glucose, lactate, triglycerides, uric acid, and choles-
terol were monitored preprandially and twice throughout the
night during the first 24 hours of the hospital admission.
Laboratory procedures
Inulin clearance studies were performed during water diure-
sis according to standard protocols. Inulin concentrations in
urine and plasma were determined by standard methods [15j.
Creatinine clearance, total urinary protein, and albumin excre-
tion were determined from timed urine collections. All values
for GFR were normalized to mI/mm/I .73 m2. Control normal
data for these assessments of GFR were obtained from the work
of our group [16, 17] and the literature [II]. Albumin excretion
in the urine was determined by an enzyme-linked immunoassay
[18]. Data in children reflect no size- or age-related changes
requiring standardization of values in terms of surface area [19];
the normal urinary albumin excretion rate (UaIbV) is less than
20 g/min.
Results
Table I presents clinical information concerning the study
subjects. The patients were almost evenly divided as to sex (8
female, 6 male). Eleven of these patients had GSD Type IA: 3
had type lB. The youngest patient, age 6 months, was studied
within days after the initiation of the overnight intragastric
feeding program. Seven of the children had started on the
overnight feeding regimen before the age of one year, while four
of the patients had been somewhat older (ages 4 to 14 years) at
the time the program commenced. The two oldest patients in
this series (who were brothers) had never been on a dietary
regimen designed to avoid fasting.
Two of the patients (6 and 12) were obsese with weights
greater than 120% of ideal body weight; the rest (with exception
of patient #7) were within 10% of ideal body weight for height
and age. The height percentiles of the patients varied from
subnormal (<5%) to well within the normal range (50 to 75%).
In general, the patients who had been on the program for a
longer period of time and who had been compliant in its
implementation demonstrated "catch-up" growth which place
them within the normal percentiles, as shown by other workers
[4]. Blood pressure was elevated in patient 13, intermittently
raised in patient 11 and normal in the others, The dietary
protein intake at the time of study, as calculated from urinary
urea nitrogen excretion, was significantly greater than RDA
recommendations in only four young patients (patients 2, 3, 4
and 5). These values were consistent with the protein intake as
judged by dietary recall.
Other important clinical chemistry data for the patients are
given in Table 2. Normal values are given at the bottom of the
Table. The uric acid concentrations were normal in seven
individuals, minimally elevated in four and above 7 mg/dl in
only three subjects. The observations obtained at the time of
the renal studies were consistent with the levels previously
noted for these same patients. Eight of the 14 subjects were on
treatment with allopurinol. an inhibitor of xanthine oxidase.
As previously reported [20], the pre-prandial lactate concen-
trations seen in most patients remained elevated (3 to 5 mM)
when compared to normal controls (0.5 to 1.5 mM), but clearly
lower than in the untreated state (8 to 12 mM). The lactate levels
observed after the overnight infusion were generally lower than
the pre-prandial specimens. The elevated plasma lactate levels
were not accompanied by systemic acidemia (data not shown,
but venous pH measurements averaged 7.38).
The serum triglyceride concentrations were elevated in all
patients, including those who were conscientiously adhering to
the prescribed program. Cholesterol levels were higher than
normal in almost all (10 of 13) subjects.
The glucagon level was elevated in only one of the nine
patients in whom it was measured. Pre-prandial levels of growth
hormone were generally below 10 mg/mI (data not shown).
Pt.
Type
Age
at time of
Overnight
feedings Overnight program Weight Height Blood Prot. intake
Sex OSD-1 study yr started yr at time of study %JBW %ile pressure % RDA for age
I F A 0.6 Just Infusion 93 <5 98/64 120
2 F B 3.1 <1 Infusion 103 <5 90/58 240
3 F A 3.9 <I Infusion 93 <5 98/48 300
4 M A 3.9 <I Infusion 103 5 110/72 230
5 F A 6.0 <1 Infusion 110 5 110/60 160
6 M A 7.3 <I Infusion 136 20 100/62 110
7 F B 9.6 <I Infusion" 76 <5 104/70 90
8 F A 11.2 <I Infusion 109 50 128/72 60
9 M A 15.1 4 Infusion 103 5 110/80 40
10 F A 17.3 8 Cornstarch" 91 50 110/60 100
II F A 18.3 6 Cornstarch 108 75 132/92 80
12 M B 21.6 14 Cornstarch 122 5 126/76 70
13 M A 27.8 Never None 107 <5 142/98 130
14 M A 33.2 Never None
-
104 <5 128/72 140
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Table 2. Chemical parameters of control in the GSD-1 patients
Pt.
Uric acid
mg/dl
Lactate mM/liter
After overnight Triglyceride
Preprandial
-
regimen ng/di
Cholesterol Glucagon
pg/mi
1 5.8 3.4 2.5 2,830 305 ND
2 6.4 3.5 2.1 325 141 102
3 5.1 5.7 3.1 867 222 127
4 6.5 3.4 1.5 833 233 187
5 5.6 4.2 4.3 572 ND 106
6 4.6 3.0 3.0 541 220 113
7 6.2 1.2 0.9 245 193 ND
8 6.0 1.6 1.3 370 441 418
9 3,4 2.0 4.4 754 236 96
10 7.2 4.0 2.2 1,186 233 95
II 5.5 4.2 4.8 464 175 ND
12 8.3 7.8 2.0 576 514 ND
13 7.4 ND 5.2 469 312 ND
14 6.9 3.6 5.0 527 383 ND
Mean 6.1 3.7 2.9 754 278
SEM 0.3 0.5 0.4 173 30
Normal
values 2.0—6.0 0.5—1.5 0.5—1.5 70—170 40—200 50—150
Table 3. Renal evaluation of the GSD-l patients
GFR
m!/,nin/I.73 in2 Kidney size
Urinary albumin
excretion
Pt. Creatinine Tc-DTPA Inulin Ultrasound p.g/min
I 87 129 — Large 11
2 300 ND — Large 5
3 237 153 — Large 15
4 124 143 — 19
5 156 267 — Large 19
6 113 200 — ND 7
7 167 146 — NI 14
8 154 150 — 14
9 217 ND 178 29
10 152 189 188 32
Il 156 172 — Large 113
12 219 180 219 Large Proteinuria
13 137 132 — Asymmetrical Proteinuria
14 163 ND 198 Proteinuria
Mean 170 169 195
SEM 15 12 9
Top limit of normal
The renal evaluation of these patients is summarized in Table
3. The GFR data are also presented graphically in Figure I. The
degree to which the GFR was increased is quite striking. In
order of presumed specificity of measurement, the inulin clear-
ance was increased in all four of the patients in whom it was
used, with a mean SEM of 195 9 ml/min/l.73 m2 (normal:
111 6 ml/min/l.73 m2 [16]). The GFR as assessed by the
Tc-DTPA method was 169 12 ml/min/l.73 m2; 9 of the II
patients were above the normal range (120 15 [111). The
creatinine clearance was also elevated to the same degree, with
a value of 170 15 ml/min/1.73 m2 (normal: 125 7 [17]).
The three patients in this series who were above 20 years old
demonstrated gross proteinuria (range 2 to 8 g/day). Urinary
albumin excretion was normal (<20 g/min) in the youngest
patients, but significantly (29 to 113 tg/min) increased in three
patients aged 15 to 20 years.
Renal ultrasonography was performed on 13 patients. Using
the standards of Rosenbaum, Korngould and Teele [14], one
patient (7) had normal kidney size and texture, five had border-
line large kidneys (patients 4, 8, 9, 10 and 14) and six demon-
strated clear-cut nephromegaly (patients 1, 2, 3, 5, 11 and 12).
Patient #13 had asymmetric measurements, with the right
kidney being at the top limits of normal, while the left kidney
was clearly normal. There appeared to be no correlation be-
tween kidney size and the degree of glomerular hyperfiltration.
Coarsened texture or increased echogenicity was noted in 11 of
13 subjects (2, 3, 4, 5, 8. 9, 10, II, 12, 13, 14). Patient 4 was
found to have bilateral nephrolithiasis, which was determined
to be secondary to hypercalciuria.
Patients 12 and 13 underwent renal biopsies which showed
focal and global segmental glomerulosclerosis, interstitial fi-
brosis. mild to moderate diffuse mesangial proliferation, and
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Fig. I. Glomerularfiltration rate was estimated by
three methods in patients with GSD. In 14 patients,
creatinine clearance was measured, in 12 patients
plasma disappearance rates of 99mTcDTPA were
calculated, and in 4 patients, standard inulin
clearances were performed. (Eu, mean SaM.)
Normal ranges were determined from previous
studies.
focal hyalinosis. Irregular basement membrane widening was
found in one of the subjects. No evidence of immune deposits
was found by immunofluorescence techniques. No uric acid
crystals were noted on specific straining. Excessive glycogen
was demonstrated in tubular epithelial nuclei.
Discussion
This study confirms and extends the observations of Chen
and colleagues [9] that chronic renal disease is common in older
patients with GSD-I. All three individuals in this series above
the age of 20 were excreting between 2 and 8 grams of protein
per day; in addition, two other patients (ages 22 and 25) who
could not participate in our complete study collected 24-hour
urine specimens which documented proteinuria in excess of 0.5
glday. If these five patients are added to those presented by
Chen et al [9], 15 of 16 patients with GSD-1 who were older than
20 years of age had evidence of nephropathy (the one exception
was a patient said to have "partial" glucose-6-phosphatase
deficiency [91).
It would also appear from the pathological evidence that the
renal damage is specifically related to GSD-I (or to some aspect
of the disturbed physiology found in this disease), and not to an
acquired renal insult. The lesions seen on renal biopsy in our
two patients included tubular glycogen deposition, interstitial
fibrosis, and focal and global segmental sclerosis. These obser-
vations are similar to the characteristic abnormalities reported
in the three subjects studied by Chen and co-workers [91, the
three patients described by Verani and Bernstein [21], and the
one young patient reported by Jonas and co-workers [22].
The major new finding in this study is the observation that
glomerular hyperfiltration is found in virtually all patients with
GSD-I, including those with no other documented renal func-
tional abnormality. The prospective assessment of GFR in our
patients with GSD-l documented glomerular filtration rates in
the range of 170 ml/min/l.73 m2. Twelve of the 14 patients had
a clear-cut elevation of GFR by at least one of the methods
employed. The only exceptions to the elevated GFR were the
youngest patient (6 months old) and the individual who demon-
strated the most severe degree of proteinuria. It is plausible that
the baby had not yet had sufficient time to develop hyperfiltra-
tion, while the individual excreting 8 g/day of protein had
already suffered sufficient glomerular damage as to cause a
decrease to normal from a previously elevated filtration rate.
The pathologic lesions seen in the glomeruli of the GSD-I
patients are quite similar to the changes seen in the partially
nephrectomized animal model where single nephron glomerular
pressure, plasma flow and filtration rate have all been docu-
mented to be high [10]. The progressive renal disease seen in
GSD is therefore compatible with the role of hemodynamic
factors (increased flow and/or pressure) in the initiation and/or
progression of glomerular damage as postulated by Brenner
[231. On the other hand, the increased GFR may not be etiologic
for the renal damage, but merely associated with other factors
more responsible. Structural damage and proteinuria could
possibly result from the metabolic abnormalities seen even in
treated patients. Among the possibilities would be the pro-
longed presence of hyperlipidemia, which has been implicated
in other instances of progressive renal damage [24].
The specific mechanism responsible for the elevated glomer-
ular filtration rate seen in patients with GSD-I is unclear. The
known deficiency of glucose-6-phosphatase in the kidney has
been suggested as the explanation for the increased GFR [91.
1348 Baker ci a!: Hyperfihtration and renal disease in GSD-I
300
0
x
0
0
250
200
1500
100
50
x
x
xIi°i
0
I I
Creatinine
clearance
Tc-
DTPA
Inulin
Baker ci a!: Hyperfiltration and renal disease in GSD-I 1349
However, the mechanism whereby an enzyme deficiency ap-
parently restricted to the tubular epithelium causes glomerular
hyperfiltration is obscure.
Other possible causes of glomerular hyperfiltration were
sought in our patients. No relationship was noted between the
GFR and other variables such as: protein intake, deviation from
norms of height or weight, blood pressure, or degree of eleva-
tion of lipid levels. Increased glomerular filtration has been
noted in diabetes mellitus and pregnancy, clinical conditions
which were not found in our patients with GSD-I. The admin-
istration of glucagon or growth hormone to both normal and
diabetic individuals results in an increase in the GFR of
approximately 10% [25, 26]. Glucagon and growth hormone
levels have been shown to be high in untreated GSD-I patients
[27], but our data and those of Slonim et al [28] indicate that
these are normalized with the introduction of the frequent
feeding regimen.
Modern therapy for GSD-I dictates that patients continuously
absorb glucose in order to avoid the abnormalities consequent
to a fall in serum glucose concentration, which makes this
situation superficially akin to the continuous feeding of hyper-
alimentation and hyperphagia. Nephromegaly [29] and hyper-
filtration [301 have been seen with hyperalimentation therapy.
Hyperphagia and obesity in an animal model has been associ-
ated with nephromegaly, glomerular hyperfiltration, albuminu-
na and focal glomerulosclerosis [31, 32]. However, only two of
the study patients were obese. More importantly, patients 13
and 14 had never been treated with a continuous feeding
regimen, but developed the same renal lesion as seen in the
other GSD subjects. This strongly suggests that the nephrop-
athy results from an abnormality associated with the disease
itself, and not from the current continuous feeding treatment
approach to GSD-I.
Excess protein intake is known to produce glomerular hyper-
filtration, and restrictions concerning the type of carbohydrate
intake in the patients with GSD-I raise the possibility of an
increase in the protein consumed by the individuals. In addi-
tion, some groups [27] have advocated the use of Vivonex® as
the basic overnight infusion; Vivonex® contains 10% protein.
However, the overnight program used in our institution utilizes
glucose alone, infused at the rate of 100 to 150% of the hepatic
glucose production rate [20]. Moreover, on direct examination
of protein intake (dietary history and urinary urea excretion),
only 4 of the 14 subjects were found to be consuming protein
greatly in excess of the RDA recommendations for age. While
increased protein intake cannot account for the elevated GFR,
it is possible that a high protein intake may contribute to the
hyperfiltration process in GSD-I, similar to what has been noted
in diabetes [33]. Reduced protein diets may afford a therapeutic
approach for these patients.
It has recently been reported that the administration of lactic
acid can increase GFR in both normal and diabetic subjects
[34]. The mean level of lactate achieved after infusion was 1.3
m in the diabetic patients, a concentration not as high as the
lactate values often seen in GSD-I individuals. The possibility
thus arises that persistently elevated levels of lactate might play
a role in the mechanism of hyperfiltration. In line with this
reasoning, it is also plausible that the increased levels of
alanine, proline and glutamate in patients with GSD-I [27] might
be involved in the process leading to hyperfiltration. Adminis-
tration of these amino acids by stomach tube to dogs increases
the GFR by 30 to 40%, similar to the increase in GFR after the
ingestion of meat [35].
The evolution of renal disease in patients with GSD-I would
appear to be analogous with what has been described for the
nephropathy associated with insulin-dependent diabetes melli-
tus (IDDM) [36]. A long period of "silent" disease exists, with
glomerular hyperfiltration as the only demonstrable renal ab-
normality. After 15 to 20 years, some patients begin to show an
increase in the rate of urinary albumin excretion suggestive of
early glomerular damage associated with changes in glomerular
permeability. In IDDM, this stage has been referred to as
"incipient nephropathy" [35]. Overt nephropathy with obvious
proteinuria is found after 20 years of disease, with progression
to more profound renal damage and ultimate renal failure. A
GFR in the normal range during the period of overt nephrop-
athy may signal the start of a progressive fall. Further studies of
the renal lesion in GSD-I (including the mechanism underlying
the observed hyperfiltration and interventions designed to pre-
vent or delay glomerular damage) are likely to yield insights of
importance and relevance to that more common metabolic
disease, diabetes.
In summary, we have identified glomerular hyperfiltration as
a common finding in patients with GSD-I. Virtually all GSD-I
patients beyond the age of one year demonstrate an increase in
GFR averaging almost 50%. Glomerular damage is reflected
initially by an increased albumin excretion rate, but appears to
progress to gross proteinuria. These changes are accompanied
by the presence on renal biopsy of focal and global glomerulo-
sclerosis and interstitial fibrosis. Because of this sequence of
events, it is possible that the renal damage seen in GSD-I may
be an example of glomerular hyperfiltration-hypertension me-
diated disease, although its specific etiologic role remains to be
determined.
Acknowledgments
This study was supported by grants from the National Institutes of
Health (#RR 00240, P30-DK 19525, T32 DK 07314, and DK 39727) and
the Juvenile Diabetes Foundation (187558).
Reprint requests to Lester Baker, M.D., Division of Endocrinology!
Diabetes, The Children's Hospital of Philadelphia, 34th Street & Civic
Center Blvd., Philadelphia, Pennsylvania /9104, USA.
References
1. HOWELL RR, WILLIAMS JC: The glycogen storage diseases, in The
Metabolic Basis of Inherited Disease (5th ed), edited by STANBURY
JB, WYNGAARDEN JB, FREDRICKSON DS, GOLDSTEIN JL, BROWN
MS. New York. McGraw Hill Book Co., 1983, pp. 141—166
2. LANGE AJ, ARI0N Wi, BEAUDET AL: Type lB glycogen storage
disease is caused by a defect in the glucose-6-phosphate translocase
of the microsomal glucose-6-phosphatase system. J Biol Chem 225:
8381—8383, 1980
3. BURCI-IELL A, JUNG RI, LANG CC, BENNET W, SHEPHERD AN:
Diagnosis of type IA and type IC glycogen storage disease in adults.
Lance! i: 1059—1062, 1987
4. GREENE HL, SLONIM AE, BURR IA: Type I glycogen storage
disease: A metabolic basis for advances in treatment. Adv Pediatr
26:63—92, 1979
5. HOLLING HE: Gout and glycogen storage disease. Anna! Intern
Med 58:654—663. 1963
6. STEIM H. ZOLLINGER HU: TOdliche schrumpfniere bei glykogen-
1350 Baker et al: Hyperfiltration and renal disease in GSD-I
speicherkrankheit typ von Gierke. Kiln Wochenschr 45:295—299,
1967
7. ALEPA FP, HOWELL RR, KLINENBERG JR, SEEGMILLER JE: Rela-
tionships between glycogen storage disease and tophaceous gout.
Am J Med 42:58—66, 1967
8. BECK LH: Requiem for gouty nephropathy. Kidney mt 30:280—287,
1986
9. CHEN Y-T, COLEMAN RA, SCHEINMAN JI, KOLBECK PC, SIDBURY
JV: Renal disease in type I glycogen storage disease. N Engi J Med
318:7—lI, 1988
10. HOSTETTER TH, OLSON JL, RENNKE HG, VENKATACHALAM MA,
BRENNER BM: Hyperfiltration in remnant nephrons: A potentially
adverse response to renal ablation. Am J Physiol 241:F85—F93,
1981
11. HUTTUNEN K, HIJTTUNEN N-P, KolvuLA A, AH0NEN A, PUUKKA
R: SSmTcDTpAa useful clinical tool for the measurement of
glomerular filtration rate. Scandf UrolNephrol 16:237—241, 1982
12. MARON BJ, STEINMAN TI, MITCH WE: Method for estimating
nitrogen intake of patients with chronic renal failure. Kidney ml 27:
58—65, 1985
13. Protein and Amino Acids, in Recommended Daily Allowances. 9th
Edition. Washington, D.C., National Academy of Sciences, 1980,
pp. 39—54
14. ROSENBAUM DM, KORNGOULD E, TEELE R: Sonographic assess-
ment of renal length in normal children. Am J Roenig 142:467—469,
1984
IS. HEYROVSKY A: A new method for the determination of inulin in
plasma and urine. Clin Chem Acta l:470—474, 1956
16. GOLDFARB 5, WALKER B, AGUS ZS: The uricosuric action of
oxaprozin. J Clin Pharmacol 25: l44—l49, 1985
17. GOLDSTEIN C, WALKER B, GOLDFARB S: Comparative effects of
oxaprozin on renal hemodynamic and electrolyte excretion. Semin
Rheumatol l5(Suppl):27—35, 1985
18. FIELDING BA, PRICE DA, HOULTON CA: Enzyme immunoassay
for urinary albumin. Clin Chem 29:355—357, 1983
19. ROWE DJF, HAYWARD M, BAGGAH H, BETTS P: Effect of glycemic
control and duration of disease on overnight albumin excretion in
diabetic children. Brit Med J 289:957—959, 1984
20. STANLEY CA, MILLS JL, BAKER L: Intragastric feeding in type I
glycogen storage disease: Factors affecting the control of lactic
acidemia. Pediatr Res 15:1504—1508. 1981
21. VERANI R, BERNSTEIN J: Renal glomerular and tubular abnormal-
ities in glycogen storage disease type I. Arch Pathol Lab Med 112:
271—274, 1988
22. JONAS AJ, VERANI RR. HOWELL R, CONLEY SB: Hypertension in
a child with type IA glycogen storage disease. Am J Kid Dis II:
264—266, 1988
23. BRENNER BM: Hemodynamically mediated glomerular injury and
the progressive nature of kidney disease. Kidney mt 23:647—655,
1983
24. KLAHR S,SCHREINER 0, ICHIKAWA I: The progression of renal
disease. N Engl J Med 318: 1657—1666, 1988
25. PARVING HH, CHRISTIANSEN JS, NOER I, TRONIER B, MOGENSEN
CE: The effect of glucagon infusion on kidney function in short-
term insulin-dependent juvenile diabetics. Diabetologia 19:350—
354, 1980
26. CHRISTIANSEN JS, GAMMELGAARD J, Oisov H, ANDERSON AR,
TILMER S. PARVING HH: Kidney function and size in normal
subjects before and during growth hormone administration for one
week. EurJClin Invest 11:487—490, 1981
27. GREENE HL, SLONIM AE, O'NEILL JA JR, Burr IM: Continuous
nocturnal intragastric feeding for management of type I glycogen
storage disease. N Engi J Med 294:423—425, 1976
28. SL0NIM AE, LACY WW, TERRY A, GREENE HL, BURR IM:
Nocturnal intragastric therapy in type I glycogen storage disease:
Effect on hormonal and amino acid metabolism. Metabolism 28:
707—715, 1979
29. COCHRAN ST, PAGANI JJ, BARBARIC ZL: Nephromegaly in hyper-
alimentation. Radiology 130:603—606, 1979
30. BATUMAN V, DREI5BACH A, MAESAKA JK, ROTHKOPF M, Ross E:
Renal and electrolyte effects of total parenteral nutrition. J Parent
Enieral Nutr 8:546—55 I, 1984
31. KA5I5KE BL, CLEARY MP, O'DONNELL MP, KEANE WF: Effects
of genetic obesity on renal structure and function in the Zucker rat.
J Lab Clin Med 106:598—604, 1985
32. O'DONNELL MP, KASISKE BL, CLEARY MP, KEANE WF: Effects
of genetic obesity on renal struction and function in the Zucker rat:
Micropuncture studies. J Lab Clin Med 106:605—610, 1985
33. KUPIN WL, CORTES P, DUMLER F, FELDCAMP CS, KILATES MC,
LEVIN NW: Effect on renal function of change from high to
moderate protein intake in type 1 diabetic patients, Diabetes 36:73—
79, 1987
34. TREVISAN R, NO5ADINI R, FIORETTO P. VELU5sI M, AVOGARO A,
DUNER E, L0RI E, DORIA A, MERKEL C, VALERIO A, CREPALIDI
G: Metabolic control of kidney hemodynamics in normal and
insulin-dependent diabetic subjects. Diabetes 36:1073—1081, 1987
35. LEE KE, SUMMERILL RA: Glomerular filtration rate following
administration of individual amino acids in conscious dogs. Q J Exp
Phvsiol 67:459—465, 1982
36. MOGENSEN CE, CHRISTENSEN CK, VITTINGHUS E: The stages in
diabetic renal disease. Diabetes 32 (Suppl 2):64—78, 1983
